Immunome, Inc. $IMNM Position Trimmed by Candriam S.C.A.

Key Points

• Candriam cut its Immunome stake by 28% in the third quarter, selling 190,279 shares and ending the period with 489,853 shares valued at about $10.6 million. Institutional investors and hedge funds collectively owned 44.58% of the company.
• Analyst views are broadly positive: Immunome has a “Moderate Buy” consensus rating and an average price target of $34.25, based on 13 Buy, one Hold, and one Sell rating.
• Immunome reported a quarterly loss of $0.76 per share, wider than analysts’ expected loss of $0.61. The stock opened at $19.36, below its 50-day and 200-day moving averages.

Candriam S.C.A. lessened its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 28.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 489,853 shares of the company's stock after selling 190,279 shares during the period. Candriam S.C.A. owned approximately 0.43% of Immunome worth $10,575,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Alps Advisors Inc. raised its holdings in Immunome by 31.5% in the third quarter. Alps Advisors Inc. now owns 150,502 shares of the company's stock valued at $3,237,000 after buying an additional 36,062 shares during the period. Sterling Capital Management LLC lifted its holdings in shares of Immunome by 840.0% during the 3rd quarter. Sterling Capital Management LLC now owns 3,478 shares of the company's stock valued at $75,000 after acquiring an additional 3,108 shares in the last quarter. GK Wealth Management LLC acquired a new position in shares of Immunome during the 3rd quarter valued at $71,000. Integrated Wealth Concepts LLC acquired a new position in shares of Immunome during the 2nd quarter valued at $27,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Immunome during the 2nd quarter worth $576,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on IMNM. Truist Financial increased their price target on Immunome from $37.00 to $38.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunome in a report on Thursday, October 15th. Alliance Global Partners started coverage on Immunome in a research report on Monday, September 21st. They set a "buy" rating and a $32.00 price target on the stock. William Blair began coverage on Immunome in a report on Friday, October 16th. They issued an "outperform" rating for the company. Finally, HC Wainwright restated a "buy" rating on shares of Immunome in a report on Tuesday, October 27th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Immunome has a consensus rating of "Moderate Buy" and an average price target of $34.25.

Insider Buying and Selling

In other news, insider Jack Higgins sold 13,200 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the transaction, the insider directly owned 65,050 shares in the company, valued at approximately $1,647,066. This represents a 16.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00. Following the sale, the director directly owned 92,211 shares of the company's stock, valued at $2,512,749.75. The trade was a 10.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 7.21% of the company's stock.

Immunome Stock Performance

NASDAQ:IMNM opened at $19.36 on Tuesday. Immunome, Inc. has a one year low of $15.46 and a one year high of $30.06. The business's 50-day simple moving average is $21.33 and its 200 day simple moving average is $22.37. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -7.65 and a beta of 2.68.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.15). On average, equities research analysts predict that Immunome, Inc. will post -2.48 EPS for the current year.

Immunome Company Profile

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need.

The company's research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

Immunome became a publicly traded company in 2023 following a merger with Morphimmune and a combination with Ayala Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.